Recently released draft congressional legislation to reform the 340B program has drawn positive initial reactions from across the range of [...] …
Year: 2024
Lobbying on 340B issues reached a record level in 2023, according to annual tallies of congressional lobbying disclosures. That flurry [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The Health Resources and Services Administration (HRSA) conducts randomized audits to assess compliance with the 340B drug pricing program, a federal initiative aimed at providing discounted medications to eligible entities. With more than 13,100 parent entities participating in 340B, this increased
…
A federal district judge last week denied two community health centers’ antitrust claims against four major diabetes drug manufacturers over [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eight Mississippi state senators have introduced a bill to bar drugmakers from restricting 340B contract pharmacy use and pharmacy benefit [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A California hospital last week reached a settlement to pay the state of California and the U.S. government a combined [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker GlaxoSmithKline has posted another refund notice to 340B providers related to purchases of its high-earning asthma drugs. A Jan. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After more than six months of long meetings with stakeholders, a bipartisan group of six senators released draft legislation Friday [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent federal district court ruling on the 340B patient definition created a “gray area” for 340B providers and drugmakers, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal auditors determined terminations from the 340B program were required for either a covered entity site or a contract pharmacy [...] …
